☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
bayer
Bayer Reports the Initiation of P-III (SOHO-02) Study of BAY 2927088 to Treat Non-Small Cell Lung Cancer (NSCLC)
August 30, 2024
Bayer Partners with NextRNA Therapeutics to Develop Small Molecules Targeting Long Non-Coding RNAs (lncRNAs) for Oncology
August 29, 2024
Bayer Reports the P-III (FINEARTS-HF) Study Data of Finerenone to Prevent Heart Failure with Preserved Ejection Fraction
August 5, 2024
Bayer Submits NDA of Elinzanetant, Seeking Approval in the US for Vasomotor Symptoms Treatment
August 2, 2024
Bayer Provides Update on P-III (ARANOTE) Study of Darolutamide to Treat Metastatic Hormone-Sensitive Prostate Cancer
July 17, 2024
Bayer and Evotec Join Forces to Develop Treatment for Cardiovascular Diseases
April 30, 2024
Load more...
Back to Home